Credit Suisse Downgrades Becton, Dickinson and Co (BDX) to Neutral
More News related to BDX
- BD to Present at Investor Healthcare Conferences
- Becton Dickinson (BDX) Reports In-Line Q4 EPS; Guides
- BD Announces Results for Fourth Fiscal Quarter and Full Year
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- University of Michigan Wolverine Venture Fund Continues Track Record of Industry Firsts
More News related to Downgrades
- Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
- Barrington Downgrades Perceptron (PRCP) Following Q1 Miss
- DA Davidson Issues Mid-Day Downgrade on FEI Company (FEIC)
- D.A. Davidson Downgrades Sterling Construction (STRL) to Neutral
- BMO Capital Downgrades MF Global (MF) to Market Perform
Credit Suisse downgrades Becton, Dickinson and Co (NYSE: BDX) from Outperform to Neutral.
Becton, Dickinson and Company (BD), is a medical technology company engaged in the manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public.
Related Categories
DowngradesStocks Mentioned
+0.23Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
